
Sign up to save your podcasts
Or


Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
By Mayo Clinic4.4
268268 ratings
Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

139 Listeners

319 Listeners

698 Listeners

498 Listeners

250 Listeners

260 Listeners

3,345 Listeners

1,154 Listeners

195 Listeners

91 Listeners

512 Listeners

363 Listeners

12 Listeners

253 Listeners

18 Listeners

15 Listeners

9 Listeners

429 Listeners

371 Listeners

45 Listeners

14 Listeners